Matsuzuka Sakae, Iseki Yasuhito, Fukuoka Tatsunari, Shibutani Masatsune, Nagahara Hisashi, Miki Youichiro, Yoshii Mami, Tamura Tatsurou, Toyokawa Takahiro, Tanaka Hiroaki, Lee Shigeru, Muguruma Kazuya, Ohira Masaichi
Dept. of Surgery, Osaka City University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2021 Mar;48(3):385-387.
A 50s old woman admitted to our hospital with anal pain, who was diagnosed as rectal gastrointestinal stromal tumor (GIST). After neoadjuvant therapy with imatinib mesylate for 6 months, the tumor reduced by 75% from its original size and anus preserving operation(low anterior resection)was performed. After operation adjuvant therapy with imatinib mesylate was performed for 2 years and 6 months. The patient is alive without recurrence 5 years after surgery. It is suggested that neoadjuvant therapy with imatinib mesylate is useful and safety for large rectal GIST, from the standpoint of anal preservation.
一名50多岁的女性因肛门疼痛入院，被诊断为直肠胃肠道间质瘤（GIST）。在接受甲磺酸伊马替尼新辅助治疗6个月后，肿瘤体积较原大小缩小了75%，并进行了保肛手术（低位前切除术）。术后进行了2年6个月的甲磺酸伊马替尼辅助治疗。患者术后5年存活且无复发。从保肛的角度来看，甲磺酸伊马替尼新辅助治疗对于大型直肠GIST是有效且安全的。
